|
1
|
Ezra A, Rabinovich-Nikitin I,
Rabinovich-Toidman P and Solomon B: Multifunctional effect of human
serum albumin reduces Alzheimer's disease related pathologies in
the 3xTg mouse model. J Alzheimers Dis. 50:175–188. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Keaney J, Walsh DM, O'Malley T, Hudson N,
Crosbie DE, Loftus T, Sheehan F, McDaid J, Humphries MM, Callanan
JJ, et al: Autoregulated paracellular clearance of amyloid-β across
the blood-brain barrier. Sci Adv. 1:e15004722015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xi YD, Li XY, Ding J, Yu HL, Ma WW, Yuan
LH, Wu J and Xiao R: Soy isoflavone alleviates Aβ1-42-induced
impairment of learning and memory ability through the regulation of
RAGE/LRP-1 in neuronal and vascular tissue. Curr Neurovasc Res.
10:144–156. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Do TM, Dodacki A, Alata W, Calon F,
Nicolic S, Scherrmann JM, Farinotti R and Bourasset F:
Age-dependent regulation of the Blood-brain barrier Influx/Efflux
equilibrium of amyloid-β peptide in a mouse model of Alzheimer's
disease (3xTg-AD). J Alzheimers Dis. 49:287–300. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Matsumoto K, Chiba Y, Fujihara R, Kubo H,
Sakamoto H and Ueno M: Immunohistochemical analysis of transporters
related to clearance of amyloid-β peptides through
blood-cerebrospinal fluid barrier in human brain. Histochem Cell
Biol. 144:597–611. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Deane R, Singh I, Sagare AP, Bell RD, Ross
NT, LaRue B, Love R, Perry S, Paquette N, Deane RJ, et al: A
multimodal RAGE-specific inhibitor reduces amyloid beta-mediated
brain disorder in a mouse model of Alzheimer disease. J Clin
Invest. 122:1377–1392. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Erickson MA, Hartvigson PE, Morofuji Y,
Owen JB, Butterfield DA and Banks WA: Lipopolysaccharide impairs
amyloid β efflux from brain: Altered vascular sequestration,
cerebrospinal fluid reabsorption, peripheral clearance and
transporter function at the blood-brain barrier. J
Neuroinflammation. 9:1502012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ko SY, Ko HA, Chu KH, Shieh TM, Chi TC,
Chen HI, Chang WC and Chang SS: The possible mechanism of advanced
glycation end products (AGEs) for Alzheimer's disease. PLoS One.
10:e01433452015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang X, Yu S, Hu JP, Wang CY, Wang Y, Liu
HX and Liu YL: Streptozotocin-induced diabetes increases amyloid
plaque deposition in AD transgenic mice through modulating
AGEs/RAGE/NF-kB pathway. Int J Neurosci. 124:601–608. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lv C, Wang L, Liu X, Yan S, Yan SS, Wang Y
and Zhang W: Multi-faced neuroprotective effects of geniposide
depending on the RAGE-mediated signaling in an Alzheimer mouse
model. Neuropharmacology. 89:175–184. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Di BB, Li HW, Li WP, Shen XH, Sun ZJ and
Wu X: Pioglitazone inhibits high glucose-induced expression of
receptor for advanced glycation end products in coronary artery
smooth muscle cells. Mol Med Rep. 11:2601–2607. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xiong MQ: Theory on Exogenous Febrile
Disease. China Press of Traditional Chinese Medicine; Beijing:
2007
|
|
13
|
Yu B, Zhou C, Zhang J, Ling Y, Hu Q, Wang
Y and Bai K: Latest study on the relationship between pathological
process of inflammatory injury and the syndrome of spleen
deficiency and fluid retention in Alzheimer's disease. Evid Based
Complement Alternat Med. 2014:7435412014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sang F: Experimental research on the
mechanism of Alzheimer's disease. J Tradit Chin Med. 6:685–687.
2011.
|
|
15
|
National Research Council: Guide for the
Care and Use of Laboratory Animals: Eighth EditionGuide for the
Care & Use of Laboratory Animals. The National Academies Press;
pp. 1072–1073. 2010
|
|
16
|
Maurice T, Lockhart BP and Privat A:
Amnesia induced in mice by centrally administered beta-amyloid
peptides involves cholinergic dysfunction. Brain Res. 706:181–193.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cheng YF, Wang C, Lin HB, Li YF, Huang Y,
Xu JP and Zhang HT: Inhibition of phosphodiesterase-4 reverses
memory deficits produced by Aβ25-35 or Aβ1-40 peptide in rats.
Psychopharmacology (Berl). 212:181–191. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kwon SH, Lee HK, Kim JA, Hong SI, Kim SY,
Jo TH, Park YI, Lee CK, Kim YB, Lee SY and Jang CG: Neuroprotective
effects of Eucommia ulmoides, Oliv. Bark on amyloid beta
(25–35)-induced learning and memory impairments in mice. Neurosci
Lett. 487:123–127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Klunk WE, Jacob RF and Mason RP:
Quantifying amyloid beta-peptide (Abeta) aggregation using the
Congo red-Abeta (CR-abeta) spectrophotometric assay. Anal Biochem.
266:66–76. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eisele YS, Obermüller U, Heilbronner G,
Baumann F, Kaeser SA, Wolburg H, Walker LC, Staufenbiel M,
Heikenwalder M and Jucker M: Peripherally applied Abeta-containing
inoculates induce cerebral beta-amyloidosis. Science. 330:980–982.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Golden HL, Agustus JL, Nicholas JM, Schott
JM, Crutch SJ, Mancini L and Warren JD: Functional neuroanatomy of
spatial sound processing in Alzheimer's disease. Neurobiol Aging.
39:154–164. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu B: Study on the relationship between
Alzheimer's disease and the syndrome of spleen deficiency and fluid
retention based on Lingguizhugantang's intervention of Aβ-induced
inflammatory injury (unpublished PhD dissertation). Nanjing
University of TCM. 2015.
|
|
24
|
Harrington KD, Lim YY, Gould E and Maruff
P: Amyloid-beta and depression in healthy older adults: A
systematic review. Aust N Z J Psychiatry. 49:36–46. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jeynes B and Provias J: Evidence for
altered LRP/RAGE expression in Alzheimer lesion pathogenesis. Curr
Alzheimer Res. 5:432–437. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Deane R, Bell RD, Sagare A and Zlokovic
BV: Clearance of amyloid-beta peptide across the blood-brain
barrier: Implication for therapies in Alzheimer's disease. CNS
Neurol Disord Drug Targets. 8:16–30. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Christensen DD: Higher-dose (23 mg/dayay)
donepezil formulation for the treatment of patients with
moderate-to-severe Alzheimer's disease. Postgrad Med. 124:110–116.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nordberg A: Mechanisms behind the
neuroprotective actions of cholinesterase inhibitors in Alzheimer
disease. Alzheimer Dis Assoc Disord. 20 2 Suppl 1:S12–S18. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rogers SL, Farlow MR, Doody RS, Mohs R and
Friedhoff LT: A 24-week, double-blind, placebo-controlled trial of
donepezil in patients with Alzheimer's disease. Donepezil Study
Group. Neurology. 50:136–145. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Agboton C, Mahdavian S, Singh A, Ghazvini
P, Hill A and Sweet A: Impact of nighttime donepezil administration
on sleep in the older adult population: A retrospective study.
Mental Health Clinician. 4:257–259. 2014. View Article : Google Scholar
|
